Mesoblast Analyst Ratings
Mesoblast Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/21/2023 | 1197.71% | Cantor Fitzgerald | → $17 | Reiterates | Overweight → Overweight |
| 08/31/2023 | — | Jefferies | Upgrades | Hold → Buy | |
| 08/31/2023 | 1197.71% | Cantor Fitzgerald | $23 → $17 | Maintains | Overweight |
| 08/07/2023 | — | Maxim Group | Downgrades | Buy → Hold | |
| 08/04/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 08/04/2023 | 52.67% | Piper Sandler | $7 → $2 | Downgrades | Overweight → Neutral |
| 08/04/2023 | 14.5% | Chardan Capital | $2 → $1.5 | Maintains | Sell |
| 05/30/2023 | 52.67% | Chardan Capital | $2.5 → $2 | Maintains | Sell |
| 03/01/2023 | 90.84% | Chardan Capital | → $2.5 | Reiterates | → Sell |
| 02/01/2023 | 1655.73% | Cantor Fitzgerald | → $23 | Reiterates | → Overweight |
| 12/06/2022 | — | Jefferies | Downgrades | Buy → Hold | |
| 09/06/2022 | 434.35% | Piper Sandler | → $7 | Initiates Coverage On | → Overweight |
| 06/03/2022 | 90.84% | Chardan Capital | $6.5 → $2.5 | Maintains | Sell |
| 08/31/2021 | 396.18% | Chardan Capital | $7.5 → $6.5 | Maintains | Sell |
| 04/07/2021 | — | Maxim Group | Upgrades | Hold → Buy | |
| 01/19/2021 | — | Jefferies | Downgrades | Buy → Hold | |
| 12/22/2020 | — | Maxim Group | Downgrades | Buy → Hold | |
| 12/04/2020 | 472.52% | Chardan Capital | $5.5 → $7.5 | Downgrades | Neutral → Sell |
| 11/20/2020 | 1426.72% | HC Wainwright & Co. | $19 → $20 | Maintains | Buy |
| 10/22/2020 | 816.03% | RBC Capital | → $12 | Initiates Coverage On | → Sector Perform |
| 10/02/2020 | 1350.38% | HC Wainwright & Co. | $21 → $19 | Maintains | Buy |
| 05/28/2020 | 1503.05% | HC Wainwright & Co. | $14 → $21 | Reiterates | → Buy |
| 10/22/2019 | 1655.73% | Cantor Fitzgerald | → $23 | Assumes | → Overweight |
| 01/31/2019 | 396.18% | HC Wainwright & Co. | → $6.5 | Assumes | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 09/21/2023 | 1197.71% | 坎托·菲茨杰拉德 | → 17 美元 | 重申 | 超重 → 超重 |
| 08/31/2023 | — | 杰富瑞 | 升级 | 持有 → 买入 | |
| 08/31/2023 | 1197.71% | 坎托·菲茨杰拉德 | 23 美元 → 17 美元 | 维护 | 超重 |
| 08/07/2023 | — | Maxim 集团 | 降级 | 买入 → 持有 | |
| 08/04/2023 | — | 威廉布莱尔 | 降级 | 跑赢大盘 → 市场表现 | |
| 08/04/2023 | 52.67% | 派珀·桑德勒 | 7 美元 → 2 美元 | 降级 | 超重 → 中性 |
| 08/04/2023 | 14.5% | 查丹资本 | $2 → 1.5 美元 | 维护 | 卖出 |
| 05/30/2023 | 52.67% | 查丹资本 | 2.5 美元 → 2 美元 | 维护 | 卖出 |
| 03/01/2023 | 90.84% | 查丹资本 | → 2.5 美元 | 重申 | → 卖出 |
| 02/01/2023 | 1655.73% | 坎托·菲茨杰拉德 | → 23 美元 | 重申 | → 超重 |
| 12/06/2022 | — | 杰富瑞 | 降级 | 买入 → 持有 | |
| 09/06/2022 | 434.35% | 派珀·桑德勒 | → 7 美元 | 启动覆盖范围开启 | → 超重 |
| 06/03/2022 | 90.84% | 查丹资本 | 6.5 美元 → 2.5 美元 | 维护 | 卖出 |
| 08/31/2021 | 396.18% | 查丹资本 | 7.5 美元 → 6.5 美元 | 维护 | 卖出 |
| 2021 年 7 月 4 日 | — | Maxim 集团 | 升级 | 持有 → 买入 | |
| 2021 年 1 月 19 日 | — | 杰富瑞 | 降级 | 买入 → 持有 | |
| 12/22/2020 | — | Maxim 集团 | 降级 | 买入 → 持有 | |
| 2020 年 4 月 12 日 | 472.52% | 查丹资本 | 5.5 美元 → 7.5 美元 | 降级 | 中性 → 卖出 |
| 11/20/2020 | 1426.72% | HC Wainwright & Co. | 19 美元 → 20 美元 | 维护 | 购买 |
| 2020 年 10 月 22 日 | 816.03% | 加拿大皇家银行资本 | → 12 美元 | 启动覆盖范围开启 | → 行业表现 |
| 2020 年 2 月 10 日 | 1350.38% | HC Wainwright & Co. | 21 美元 → 19 美元 | 维护 | 购买 |
| 05/28/2020 | 1503.05% | HC Wainwright & Co. | 14 美元 → 21 美元 | 重申 | → 购买 |
| 2019 年 10 月 22 日 | 1655.73% | 坎托·菲茨杰拉德 | → 23 美元 | 假设 | → 超重 |
| 01/31/2019 | 396.18% | HC Wainwright & Co. | → 6.5 美元 | 假设 | → 购买 |
What is the target price for Mesoblast (MESO)?
Mesoblast (MESO) 的目标价格是多少？
The latest price target for Mesoblast (NASDAQ: MESO) was reported by Cantor Fitzgerald on September 21, 2023. The analyst firm set a price target for $17.00 expecting MESO to rise to within 12 months (a possible 1197.71% upside). 11 analyst firms have reported ratings in the last year.
坎托·菲茨杰拉德于2023年9月21日公布了Mesoblast（纳斯达克股票代码：MESO）的最新目标股价。该分析公司将目标股价定为17.00美元，预计MESO将在12个月内上涨至1197.71％（可能上涨1197.71％）。去年有11家分析公司公布了评级。
What is the most recent analyst rating for Mesoblast (MESO)?
分析师对Mesoblast（MESO）的最新评级是多少？
The latest analyst rating for Mesoblast (NASDAQ: MESO) was provided by Cantor Fitzgerald, and Mesoblast reiterated their overweight rating.
Mesoblast（纳斯达克股票代码：MESO）的最新分析师评级由坎托·菲茨杰拉德提供，Mesoblast重申了其增持评级。
When is the next analyst rating going to be posted or updated for Mesoblast (MESO)?
Mesoblast（MESO）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mesoblast, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mesoblast was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.
分析师在进行了广泛的研究后得出了股票评级，包括阅读公开财务报表、与Mesoblast的高管和客户交谈以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。Mesoblast的最后一次评级是在2023年9月21日提交的，因此你应该预计下一个评级将在2024年9月21日左右公布。
Is the Analyst Rating Mesoblast (MESO) correct?
分析师对 mesoblast (MESO) 的评级是否正确？
While ratings are subjective and will change, the latest Mesoblast (MESO) rating was a reiterated with a price target of $0.00 to $17.00. The current price Mesoblast (MESO) is trading at is $1.31, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但重申了最新的Mesoblast（MESO）评级，目标股价为0.00美元至17.00美元。Mesoblast（MESO）的当前交易价格为1.31美元，在分析师的预测区间内。
译文内容由第三方软件翻译。